Loading data for MAZE — first visit, this takes a few seconds.

알림

Maze Therapeutics Inc. (MAZE)

NasdaqGM: MAZE · 실시간 가격 · USD

29.56

-0.86 (-2.83%)

종가 기준: Aug 26, 2026, 3:59 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

-2.83% (1D)

매수호가	19.91
시가총액	1.64B
매출 (ttm)	20M
순이익 (ttm)	-133.59M
	n/a
	-2.44
	n/a
	-9.32
P/B (ttm)	3.62
P/S (ttm)	82.16
실적 발표일	Nov 5, 2026

매도호가	35.55
거래량	97,579
평균 거래량 (20일)	550,452
시가	30.26
전일 종가	30.42
일중 범위	29.33 - 30.40
52주 범위	13.67 - 53.65
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

MAZE 소개

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready c...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jan 31, 2025

직원 수 141

상장 거래소 NasdaqGM

티커 MAZE

웹사이트 https://www.mazetx.com

전체 기업 정보

재무 실적

2025년 Maze Therapeutics의 매출은 0로, 전년 167.5M 대비 -100% 감소했습니다. 순이익은 -131.12M로, -351.04% 감소했습니다.

재무제표

어닝 서프라이즈

Maze Therapeutics가 Aug 11, 2026에 분기 실적을 발표했습니다:

매출 $20M 예상치 하회 $0, 및 Infinity% 전년 대비 성장.
EPS -0.76 예상치 하회 -0.06, 및 33.91% 전년 대비 성장.

다음 실적 발표

Maze Therapeutics Inc.의 실적 발표 예정일은 Nov 5, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1개월 전 · Zacks

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in e...

1개월 전 · Motley Fool

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

This clinical-stage biotech targeting kidney and metabolic diseases reported a notable insider sale, recent filings show.

2개월 전 · Simply Wall St.

Maze Therapeutics Phase 2 Kidney Data Sparks Questions On Upside And Risk

Maze Therapeutics (NasdaqGM:MAZE) reported positive topline results from its Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease. The company plans to advance MZE829 into a pivotal trial ...

2개월 전 · Insider Monkey

Maze Therapeutics (MAZE): 8 Oversold Stocks to Buy Right Now

Maze Therapeutics Inc. (NASDAQ:MAZE) is one of the oversold stocks to buy right now. On May 12, Maze Therapeutics highlighted in their corporate and financial update positive topline data from the Pha...

2개월 전 · Motley Fool

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?

This clinical-stage biotech advancing precision medicines reported a notable insider sale amid strong one-year share performance.

2 페이지 중 1

Maze Therapeutics Inc. (MAZE)